Section Arrow
PCVX.NASDAQ
- Vaxcyte
Quotes are at least 15-min delayed:2026/08/01 16:14 EDT
Regular Hours
Last
 54.08
-1.88 (-3.36%)
Day High 
56.3874 
Prev. Close
55.96 
1-M High
61.77 
Volume 
793.22K 
Bid
49
Ask
54.08
Day Low
53.5301 
Open
56.1 
1-M Low
52.47 
Market Cap 
8.08B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 55.51 
20-SMA 56.69 
50-SMA 52.84 
52-W High 65 
52-W Low 29.08 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.89/-4.44
Enterprise Value
8.19B
Balance Sheet
Book Value Per Share
20.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.